These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 28134308

  • 1. Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy.
    Chen YH, Lu HI, Chien CY, Lo CM, Wang YM, Chou SY, Su YY, Shih LH, Li SH.
    Sci Rep; 2017 Jan 30; 7():41785. PubMed ID: 28134308
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of Different Chemotherapy Regimens in Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy.
    Chen YH, Lu HI, Chien CY, Lo CM, Wang YM, Chou SY, Li SH.
    J Clin Med; 2020 Jan 10; 9(1):. PubMed ID: 31936858
    [Abstract] [Full Text] [Related]

  • 4. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM, Wu JL, Liufu WJ, Yu TT, Niu SQ, Bao Y, Peng F.
    Cancer Immunol Immunother; 2024 Feb 16; 73(3):55. PubMed ID: 38366287
    [Abstract] [Full Text] [Related]

  • 5. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Chen TC, Wu CT, Wang CP, Lou PJ, Ko JY, Chang YL.
    Oral Oncol; 2020 Dec 16; 111():104945. PubMed ID: 32769036
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY, Hsu CP, Yeh HL, Chuang CY, Lin JF, Chang CF.
    Kaohsiung J Med Sci; 2018 May 16; 34(5):281-289. PubMed ID: 29699635
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
    Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Huang CC, Shih LH, Chen SW, Li SH.
    BMC Cancer; 2018 Aug 20; 18(1):837. PubMed ID: 30126380
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
    Chang CL, Yuan KS, Wu SY.
    Head Neck; 2017 Jul 20; 39(7):1364-1370. PubMed ID: 28370614
    [Abstract] [Full Text] [Related]

  • 15. Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae.
    Ma L, Luo GY, Ren YF, Qiu B, Yang H, Xie CX, Liu SR, Liu SL, Chen ZL, Li Q, Fu JH, Liu MZ, Hu YH, Ye WF, Liu H.
    Chin J Cancer; 2017 Jan 11; 36(1):8. PubMed ID: 28077159
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with salvage surgery after concurrent chemoradiotherapy.
    Taguchi T, Nishimura G, Takahashi M, Shiono O, Komatsu M, Sano D, Yabuki KI, Arai Y, Yamashita Y, Yamamoto K, Sakuma Y, Oridate N.
    Int J Clin Oncol; 2016 Oct 11; 21(5):869-874. PubMed ID: 26908193
    [Abstract] [Full Text] [Related]

  • 18. Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
    Boscolo-Rizzo P, Muzzi E, Trabalzini F, Gava A, Stellin M, Da Mosto MC.
    Eur Arch Otorhinolaryngol; 2011 Sep 11; 268(9):1349-55. PubMed ID: 21258812
    [Abstract] [Full Text] [Related]

  • 19. The Clinical Outcomes of Locally Advanced Cervical Esophageal Squamous Cell Carcinoma Patients Receiving Curative Concurrent Chemoradiotherapy: A Population-Based Propensity Score-Matched Analysis.
    Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Li SH.
    Cancers (Basel); 2019 Mar 30; 11(4):. PubMed ID: 30934987
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
    Nakahara S, Takenaka Y, Ogawa K, Nishiike S, Yamamoto Y, Seo Y, Isohashi F, Suzuki O, Yoshioka Y, Sumida I, Yoshii T, Tomiyama Y, Inohara H.
    Int J Clin Oncol; 2016 Dec 30; 21(6):1030-1037. PubMed ID: 27306220
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.